SRMS
MOLECULAR TARGETsrc-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites
SRMS (src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SRMS
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | vandetanib | 4.30 | 73 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | pazopanib | 3.69 | 39 |
| 6 | canertinib | 3.53 | 33 |
| 7 | tae 684 | 3.43 | 30 |
| 8 | fedratinib | 3.40 | 29 |
| 9 | lestaurtinib | 3.04 | 20 |
| 10 | defosbarasertib | 2.89 | 17 |
| 11 | r 406 | 2.83 | 16 |
| 12 | plx 4720 | 2.71 | 14 |
| 13 | kw 2449 | 2.64 | 13 |
| 14 | ast 487 | 2.56 | 12 |
| 15 | su 014813 | 2.20 | 8 |
| 16 | rebastinib | 2.20 | 8 |
| 17 | Sorafenib | 1.39 | 3 |
| 18 | Dasatinib | 1.10 | 2 |
About SRMS as a Drug Target
SRMS (src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented SRMS interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SRMS inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.